PCSK9抑制剂在外周动脉疾病中的应用:系统综述
本系统综述纳入4项研究共3770例PAD患者,其中FOURIER试验PAD亚组占3642例。FOURIER亚组显示,在接受背景他汀治疗的患者中,Evolocumab显著降低主要不良肢体事件(HR 0.58;95%CI 0.38-0.88)。较小规模研究报告了无截肢生存、伤口愈合、步行能力及内皮功能标志物的改善,但现有证据有限且异质。
要点
- PCSK9抑制剂可能减少PAD患者主要不良肢体事件,且未观察到不良效应
- FOURIER PAD亚组中Evolocumab较安慰剂显著降低MALEs(HR 0.58;95%CI 0.38-0.88)
- 现有证据有限、异质且具探索性,需专门设计的随机试验明确其作用
核心结论
- PCSK9抑制剂可能为PAD患者提供肢体相关获益且无不良效应,获益可能超出降脂本身。
- 当前证据有限、异质且具探索性,需专门且把握度充分的随机试验明确PCSK9抑制剂在PAD管理中的作用。
研究设计与样本
- 系统综述,遵循PRISMA指南,纳入评估PCSK9抑制剂治疗PAD患者的研究。
- 共纳入4项研究:3项随机对照试验和1项前瞻性病例系列,总计3770例患者。
- 多数参与者来自大型多中心RCT FOURIER的PAD亚组,该亚组贡献3642例患者。
主要发现
- FOURIER PAD亚组中,在接受背景他汀治疗的患者中,Evolocumab较安慰剂显著降低主要不良肢体事件(HR 0.58;95%CI 0.38-0.88)。
- 在PAD合并慢性肢体威胁性缺血患者中,较小规模研究报告无截肢生存、伤口愈合、步行能力以及内皮功能和动脉粥样硬化负荷标志物的改善。
关键数值与推荐
- FOURIER PAD亚组:Evolocumab vs 安慰剂,主要不良肢体事件HR 0.58(95%CI 0.38-0.88)。
临床怎么用
- 对于接受背景他汀治疗的PAD患者,PCSK9抑制剂可能作为降低肢体事件的附加治疗选择。
- 现有证据尚不足以支持将PCSK9抑制剂常规用于所有PAD患者以改善肢体结局,需结合个体情况并等待专门试验结果。
局限性
- 证据有限、异质且具探索性。
- 多数数据来自FOURIER PAD亚组,较小规模研究证据级别较低。
- 需专门且把握度充分的随机试验,以明确界定肢体结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dyslipidaemia is a key modifiable risk factor for peripheral arterial disease (PAD), and statin therapy for lipid-lowering is well established in its management. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors lower lipids and cardiovascular risk; however, their impact on limb-based outcomes in PAD remains uncertain. METHODS: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Studies evaluating PCSK9 inhibitor therapy in patients with PAD were eligible for inclusion. RESULTS: Four studies met the inclusion criteria and were included in the review, comprising three randomized controlled trials (RCTs) and 1 prospective case series, with a total of 3,770 patients. The majority of included participants were derived from a large multicenter RCT, FOURIER, which contributed 3,642 patients from its PAD subgroup. In the FOURIER PAD subgroup, Evolocumab significantly reduced major adverse limb events (MALEs) compared with placebo in patients receiving background statin therapy (Hazard Ratio 0.58; 95% Confidence Interval 0.38-0.88). Smaller studies in patients with PAD and chronic limb-threatening ischemia reported improvements in amputation-free survival, wound healing, walking performance, and markers of endothelial function and atherosclerotic burden. CONCLUSION: PCSK9 inhibitors appear to provide limb-related benefits in patients with PAD, without ill-effects. These benefits include decrease in MALEs and improvements in functional and physiological parameters, and may extend beyond lipid lowering alone. However, current evidence is limited, heterogeneous, and exploratory. Dedicated, adequately powered randomized trials focusing on clearly defined limb outcomes are needed to clarify the role of PCSK9 inhibitors in PAD management.
引用
- Bandukwala LM, Curley D, Bontinis A, et al. PCSK9 Inhibitors in Peripheral Arterial Disease: A Systematic Review. Ann Vasc Surg. 2026. PMID: 41895598. doi:10.1016/j.avsg.2026.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。